Aprio Wealth Management LLC Boosts Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Aprio Wealth Management LLC lifted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 515.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,807 shares of the company’s stock after acquiring an additional 15,752 shares during the period. Aprio Wealth Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in shares of Dr. Reddy’s Laboratories by 1.9% in the second quarter. Bank of New York Mellon Corp now owns 26,768 shares of the company’s stock worth $2,040,000 after purchasing an additional 489 shares during the last quarter. American Century Companies Inc. raised its position in Dr. Reddy’s Laboratories by 8.0% during the 2nd quarter. American Century Companies Inc. now owns 146,823 shares of the company’s stock worth $11,186,000 after buying an additional 10,855 shares during the last quarter. Parallel Advisors LLC lifted its stake in Dr. Reddy’s Laboratories by 13.4% during the 2nd quarter. Parallel Advisors LLC now owns 12,422 shares of the company’s stock valued at $946,000 after acquiring an additional 1,470 shares during the period. Angeles Investment Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 27.1% in the 2nd quarter. Angeles Investment Advisors LLC now owns 4,216 shares of the company’s stock valued at $321,000 after acquiring an additional 900 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Dr. Reddy’s Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after acquiring an additional 114,294 shares during the period. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on RDY. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Barclays dropped their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Down 0.7 %

RDY opened at $15.31 on Tuesday. The company has a fifty day moving average of $14.84 and a two-hundred day moving average of $15.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $13.43 and a fifty-two week high of $16.89. The stock has a market capitalization of $12.78 billion, a price-to-earnings ratio of 24.46 and a beta of 0.53.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.